BCGVaccine

Indications

①Adjuvant treatment of tumors;

②Prevention of tuberculosis;

③Treatment of asthmatic bronchitis and prevention of colds in children.

It is also used to treat bladder cancer in situ and prevent recurrence. It is used to prevent recurrence of bladder papilloma in Ta or T1 stage after transurethral resection.

Usage and Dosage

Take 2 bottles (120 mg) of this product, dissolve it in 40 to 50 ml of normal saline and shake it well. Follow the surgical catheterization procedure, insert the catheter into the bladder cavity, and inject the diluted liquid through the catheter. After the injection, the patient constantly changes positions, such as left side, right side, supine and prone, for about 30 minutes each, and removes the liquid on his own after 2 hours. For elderly patients or those who are infirm, the dosage of BCG vaccine can be reduced by half (60mg/time). BCG infusion is usually performed 1 to 2 weeks after surgery, after the damaged tissue has recovered. The dosing cycle is: once a week for a total of 6 times initially; then once every 2 weeks for a total of 3 times; and then once a month until 1 year, a total of 19 times. Check for bladder cancer recurrence every six months. If necessary, continue once a month for 1 to 2 years to consolidate the curative effect.

Adverse reactions

1. "BCG systemic reaction" may occur after use of therapeutic BCG vaccine. Clinical symptoms include: fever of 39.5℃ or above, lasting for 12 hours or more; fever of 38.5℃ or above 38.5°C for 48 hours or more; pneumonia, hepatitis, genitourinary organ dysfunction, granulomatous inflammation with biopsy; or traditional symptoms of sepsis, including poor circulation, acute dyspnea, and scattered intravascular coagulation.

2. Therapeutic BCG vaccine may cause local reactions after use. After infusion, symptoms such as frequent urination, urgency, hematuria, and difficulty urinating may occur when the bladder is stimulated by the drug liquid.

3. Low-grade fever may occur after using the therapeutic BCG vaccine. It often appears 2 to 3 hours after taking the medicine and lasts for several days. No need to stop medication or treatment, it can heal on its own. The incidence rate is relatively high, with more than half of patients often experiencing such symptoms.

4. A small number of patients feel uncomfortable and fatigued, have joint pain, and have a body temperature above 38°C after using the therapeutic BCG vaccine. In some patients, Bacillus Calmette-Guérin invades local tissues and the bacteria grow and multiply, causing urethritis, prostatitis, orchitis or epididymitis.

5. In very few patients, BCG pneumonia or hepatitis is caused by BCG passing through the blood. All patients who experience systemic reactions should stop taking the medication immediately and be treated with anti-tuberculosis drugs, symptomatic drugs, etc.

6. Death reports: Two cases of death caused by the use of BCG vaccine have been reported abroad, both related to systemic BCG reaction. One case was related to early liver alcoholism, failure to pay attention to catheter trauma and intracavitary medication. The second case may be related to not realizing the systemic BCG reaction and continuing BCG treatment.